Clinical Approach to Bleeding Between Periods
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of intermenstrual bleeding
Bleeding between periods, clinically termed intermenstrual bleeding (IMB), is one of the most common gynecological complaints encountered in clinical practice. Studies indicate that approximately 10-30% of reproductive-age women experience intermenstrual bleeding at some point, accounting for roughly 20% of all gynecological consultations. This symptom carries significant clinical importance as it may represent benign hormonal fluctuations or signal serious underlying pathology including malignancy.
Definition
Intermenstrual bleeding refers to any vaginal bleeding that occurs between expected menstrual periods in a woman with an otherwise regular menstrual cycle. This is distinct from irregular menstrual bleeding patterns and should be differentiated from other sources of bleeding such as urethral, rectal, or vulvar origins. The International Federation of Gynecology and Obstetrics (FIGO) classifies this under the broader category of abnormal uterine bleeding (AUB).
Key Epidemiology
- Prevalence: 10-30% of reproductive-age women experience intermenstrual bleeding
- Peak incidence: Highest in the first 5 years after menarche and the perimenopausal transition
- Contraceptive users: Up to 50% of hormonal contraceptive users experience breakthrough bleeding in the first 3 months
- Malignancy risk: Approximately 1-10% of postmenopausal bleeding cases are due to endometrial cancer; lower in premenopausal women
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute/Isolated | Single episode or less than 1 month | Ovulation bleeding, missed contraceptive pills, implantation bleeding, cervical trauma | Often self-limiting; evaluate if accompanied by red flags or recurrence |
| Subacute/Intermittent | 1 to 3 months | New hormonal contraception, cervical pathology, early pregnancy complications | Requires evaluation if persistent; consider contraceptive adjustment |
| Chronic/Persistent | Greater than 3 months | Structural lesions (polyps, fibroids), endometrial pathology, malignancy, chronic infection | Warrants thorough investigation including imaging and possible biopsy |
Classification by Character
Light Spotting
Description: Minimal blood, often brown or pink, not requiring sanitary protection
Common causes: Ovulation bleeding (mittelschmerz), hormonal contraceptive breakthrough bleeding, cervical ectropion, implantation bleeding
Clinical implication: Often benign, especially if predictable mid-cycle; warrants investigation if new onset in older patients or associated with other symptoms
Heavy Intermenstrual Bleeding
Description: Significant bleeding requiring sanitary protection, may contain clots
Common causes: Submucosal fibroids, endometrial polyps, pregnancy complications, malignancy, coagulopathy
Clinical implication: Higher likelihood of structural pathology; requires prompt evaluation and may need urgent intervention if hemodynamically significant
Classification by Timing in Menstrual Cycle
| Timing | Description | Suggests |
|---|---|---|
| Mid-cycle (days 12-16) | Occurs around expected ovulation | Ovulation bleeding (physiological), luteinized unruptured follicle |
| Pre-menstrual (days 21-28) | Occurs in the late luteal phase, just before expected period | Luteal phase defect, endometrial polyps, endometriosis, premenstrual spotting from declining progesterone |
| Post-menstrual (days 5-10) | Occurs shortly after menstruation ends | Residual endometrial shedding, endometrial polyps, submucosal fibroids |
| Random/Unpredictable | No consistent pattern in relation to cycle | Structural lesions (polyps, fibroids), cervical pathology, malignancy, anovulatory bleeding, infection |
| Postcoital | Occurs after sexual intercourse | Cervical ectropion, cervical polyps, cervical intraepithelial neoplasia, cervical cancer, cervicitis, vaginal atrophy |
Classification by Pattern
| Pattern | Description | Suggests |
|---|---|---|
| Cyclic/Predictable | Occurs at the same point in each menstrual cycle | Ovulation bleeding (if mid-cycle), hormonal causes, endometriosis |
| Acyclic/Unpredictable | Variable timing, no clear pattern | Structural pathology, malignancy, anovulation, infection |
| Contact-related | Provoked by intercourse or pelvic examination | Cervical lesions (ectropion, polyps, dysplasia, cancer), vaginal pathology |
| Medication-related | Temporally associated with starting or missing hormonal medications | Breakthrough bleeding from contraceptives, missed pills, anticoagulant therapy |
The FIGO PALM-COEIN Classification System
Key Framework: The FIGO (International Federation of Gynecology and Obstetrics) developed the PALM-COEIN classification to standardize the approach to abnormal uterine bleeding, including intermenstrual bleeding:
- PALM (Structural causes): Polyp, Adenomyosis, Leiomyoma (fibroid), Malignancy and hyperplasia
- COEIN (Non-structural causes): Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified
This system helps clinicians systematically consider both structural and non-structural causes of bleeding between periods.
Key Concept — The “Rule Out” Priorities:
- Pregnancy: Always exclude pregnancy first in any woman of reproductive age with abnormal bleeding
- Malignancy: Endometrial and cervical cancer must be considered, especially in women over 40, those with risk factors, or postmenopausal women
- Structural lesions: Polyps and fibroids are common and treatable causes that should be identified
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of intermenstrual bleeding
To understand intermenstrual bleeding, one must first appreciate the intricate hormonal orchestration that maintains endometrial stability throughout the menstrual cycle. The endometrium is uniquely designed to undergo cyclical growth, maturation, and shedding under the influence of estrogen and progesterone. Any disruption to this hormonal balance, structural integrity of the reproductive tract, or vascular stability can result in bleeding outside the expected menstrual window.
The Normal Menstrual Cycle and Endometrial Stability
| Phase | Days (approx.) | Dominant Hormone | Endometrial Changes | Why Bleeding Does NOT Occur |
|---|---|---|---|---|
| Menstrual Phase | 1-5 | Low estrogen and progesterone | Shedding of functional layer | Expected bleeding due to hormone withdrawal |
| Proliferative Phase | 6-14 | Rising estrogen | Endometrial proliferation, glandular growth, spiral artery development | Estrogen maintains endometrial integrity and promotes angiogenesis |
| Ovulation | ~14 | Estrogen peak, then LH surge | Follicle rupture | Brief estrogen dip may cause mid-cycle spotting in some women (physiological) |
| Secretory Phase | 15-28 | Progesterone (from corpus luteum) | Secretory transformation, decidualization, stable spiral arteries | Progesterone stabilizes endometrium, opposes estrogen-driven proliferation |
Mechanisms of Intermenstrual Bleeding
Intermenstrual bleeding occurs when the normal mechanisms maintaining endometrial stability are disrupted. The major pathophysiological mechanisms include:
Hormonal Imbalance
Mechanism: Estrogen and progesterone work in balance to maintain endometrial stability. Estrogen promotes proliferation while progesterone stabilizes and transforms the endometrium.
When disrupted: Unopposed estrogen leads to disorganized proliferation and fragile vessels; low progesterone causes instability and premature shedding.
Examples: Anovulatory cycles, hormonal contraceptive breakthrough, perimenopausal fluctuations
Structural Disruption
Mechanism: Physical lesions within the uterine cavity or cervix create abnormal surfaces prone to bleeding.
When disrupted: Polyps and fibroids have fragile surface vessels; malignant lesions have disorganized, friable vasculature.
Examples: Endometrial polyps, submucosal leiomyomas, endometrial carcinoma, cervical lesions
Vascular Abnormality
Mechanism: Abnormal blood vessel formation or fragility leads to spontaneous bleeding.
When disrupted: Arteriovenous malformations, coagulopathies, or medication-induced vessel fragility cause bleeding independent of the cycle.
Examples: Anticoagulant therapy, von Willebrand disease, uterine arteriovenous malformation
Hormonal Mechanisms in Detail
| Hormonal Scenario | Underlying Mechanism | Effect on Endometrium | Clinical Presentation |
|---|---|---|---|
| Estrogen withdrawal | Sudden drop in estrogen (e.g., mid-cycle ovulation, missed estrogen-containing pills) | Loss of endometrial support, focal necrosis and shedding | Light mid-cycle spotting, typically brief and self-limiting |
| Estrogen breakthrough | Prolonged unopposed estrogen without progesterone (anovulation) | Continued proliferation without structural support; fragile, disorganized tissue | Irregular, unpredictable bleeding; may be heavy |
| Progesterone withdrawal | Decline in progesterone (corpus luteum regression) | Triggers normal menstruation; premature decline causes early bleeding | Pre-menstrual spotting, shortened luteal phase |
| Progesterone breakthrough | Continuous progestin exposure without estrogen (progestin-only contraceptives) | Atrophic, fragile endometrium with superficial vessel exposure | Irregular spotting, common with progestin-only methods |
| Altered estrogen-to-progesterone ratio | Imbalance in the ratio during hormonal contraceptive use | Inadequate endometrial stabilization despite hormone presence | Breakthrough bleeding, especially in first 3 months of new contraceptive |
How Specific Conditions Cause Intermenstrual Bleeding
| Condition | Mechanism | Clinical Implication |
|---|---|---|
| Endometrial polyps | Localized overgrowth of endometrial tissue with fragile surface vessels that bleed easily; may outgrow their blood supply | Usually present with irregular spotting; removal is curative |
| Submucosal leiomyomas (fibroids) | Distort the endometrial cavity, stretch overlying endometrium, and compress blood vessels leading to venous congestion and surface erosion | Often cause heavy bleeding; location more important than size |
| Adenomyosis | Endometrial glands within myometrium disrupt normal myometrial contraction and vessel control; altered local prostaglandin production | May cause both heavy menstrual bleeding and intermenstrual bleeding |
| Cervical ectropion | Columnar epithelium extends onto ectocervix, which is more fragile than squamous epithelium and bleeds easily with contact | Common cause of postcoital bleeding; often benign but must rule out dysplasia |
| Endometrial hyperplasia | Excessive estrogen stimulation leads to abnormal endometrial thickening with disorganized glands and unstable vasculature | Important to diagnose as it may progress to endometrial carcinoma |
| Endometrial carcinoma | Malignant tissue with abnormal angiogenesis, fragile tumor vessels, and tissue necrosis | Must be excluded in all women over 40 with new intermenstrual bleeding or those with risk factors |
| Cervical cancer | Malignant transformation with abnormal, friable vessels; often presents with contact bleeding | Critical to exclude, especially in those overdue for cervical screening |
| Chronic endometritis | Chronic inflammation disrupts endometrial integrity and local hemostasis; often associated with plasma cell infiltration | May be subtle; consider in unexplained intermenstrual bleeding or infertility |
| Hormonal contraceptive breakthrough | Exogenous hormones alter the endometrial balance; progestins cause atrophic, fragile endometrium; low estrogen component inadequate for stability | Common in first 3 months; usually resolves; consider different formulation if persistent |
| Ovulation bleeding | Mid-cycle estrogen dip following the pre-ovulatory peak temporarily withdraws endometrial support | Physiological; light spotting with mild pelvic discomfort (mittelschmerz) |
| Implantation bleeding | Blastocyst implantation disrupts superficial endometrial vessels approximately 6-12 days after fertilization | Light spotting, may be mistaken for early period; occurs before expected menses |
Local Endometrial Factors
Prostaglandins and Vasoactive Mediators
Role: Prostaglandins (especially prostaglandin F2α and E2) regulate endometrial blood flow and myometrial contraction.
In normal menstruation: Prostaglandin release triggers vasoconstriction of spiral arteries, leading to ischemia and controlled shedding.
When disrupted: Imbalanced prostaglandin production (e.g., in adenomyosis, fibroids) leads to abnormal bleeding patterns.
Matrix Metalloproteinases (MMPs)
Role: MMPs break down the extracellular matrix during menstruation, allowing tissue shedding.
Normal regulation: MMPs are tightly controlled by tissue inhibitors (TIMPs) and hormonal signals.
When disrupted: Excessive MMP activity causes premature or excessive tissue breakdown, contributing to abnormal bleeding.
Vascular Factors and Hemostasis
| Factor | Normal Function | When Abnormal |
|---|---|---|
| Spiral arteries | Specialized vessels that constrict to stop bleeding during menstruation | Abnormal development in polyps/fibroids; impaired constriction leads to prolonged bleeding |
| Endometrial hemostasis | Local clotting factors and platelet aggregation control bleeding | Coagulopathies (von Willebrand disease, platelet disorders) impair hemostasis |
| Angiogenesis | Controlled new vessel formation during endometrial regeneration | Disorganized angiogenesis in malignancy creates fragile, bleeding-prone vessels |
Often Overlooked Mechanism: Chronic Endometritis
Chronic endometritis is an underdiagnosed cause of intermenstrual bleeding. It results from persistent low-grade infection (often polymicrobial) that disrupts normal endometrial function. The inflammation alters local hemostasis, increases vascular fragility, and prevents normal endometrial cycling. It should be considered in women with unexplained intermenstrual bleeding, especially those with a history of pelvic inflammatory disease, intrauterine device use, or infertility. Diagnosis requires endometrial biopsy showing plasma cell infiltration, and treatment with antibiotics (typically doxycycline) is often curative.
Pregnancy-Related Mechanisms
Always Consider Pregnancy Complications
In any reproductive-age woman with intermenstrual bleeding, pregnancy must be excluded first. Pregnancy-related causes of bleeding include:
- Implantation bleeding: Light spotting 6-12 days post-fertilization as blastocyst implants
- Threatened miscarriage: Bleeding with closed cervix; pregnancy may continue
- Inevitable/incomplete miscarriage: Bleeding with cervical dilation; pregnancy loss occurring
- Ectopic pregnancy: Bleeding from decidual shedding due to inadequate hormonal support from abnormally located pregnancy — a gynecological emergency
- Gestational trophoblastic disease: Abnormal trophoblastic tissue with high β-hCG and characteristic bleeding
3. History Taking
A comprehensive approach to eliciting the intermenstrual bleeding history
Red Flags — Require Urgent Evaluation
- Postmenopausal bleeding — Endometrial cancer until proven otherwise
- Heavy bleeding with hemodynamic instability — Requires urgent stabilization
- Positive pregnancy test with bleeding — Ectopic pregnancy must be excluded
- Bleeding with pelvic pain and fever — Pelvic inflammatory disease, tubo-ovarian abscess
- New intermenstrual bleeding in women over 40 — Higher malignancy risk
- Persistent postcoital bleeding — Cervical pathology including cancer
- Bleeding with significant weight loss — Malignancy, systemic disease
- Known bleeding disorder with uncontrolled bleeding — Hematology consultation
First Question — Always Rule Out Pregnancy
Before proceeding with detailed history, establish pregnancy status in every woman of reproductive age. Ask: “Is there any chance you could be pregnant? When was your last menstrual period? Are you using contraception consistently?” A urine or serum β-hCG should be obtained regardless of the answer, as patients may be unaware of early pregnancy.
Systematic History: The “BLEEDS” Approach
Use the mnemonic “BLEEDS” to ensure comprehensive history taking for intermenstrual bleeding:
- B — Bleeding characteristics: Amount (light spotting versus heavy, number of pads/tampons), color (bright red, dark, brown), duration of episodes, presence of clots
- L — Last menstrual period and cycle pattern: Date of last normal period, usual cycle length and regularity, how this bleeding differs from normal menses
- E — Events and triggers: Relation to intercourse (postcoital), timing in cycle (mid-cycle, premenstrual), relation to physical activity, recent procedures
- E — Exposures and medications: Contraceptive use (type, compliance, recent changes), hormone therapy, anticoagulants, herbal supplements
- D — Duration and development: When did this start? Single episode or recurrent? Progressive or stable? Previous similar episodes?
- S — Symptoms associated: Pain (pelvic, during intercourse), discharge, fever, urinary symptoms, bowel symptoms, systemic symptoms (weight loss, fatigue)
Key History Elements in Detail
Menstrual History
| Element | What to Ask | Why It Matters |
|---|---|---|
| Last menstrual period | “When was the first day of your last normal period?” | Establishes cycle day, helps identify if bleeding is truly intermenstrual, pregnancy dating |
| Cycle regularity | “Are your periods regular? How many days between periods?” | Irregular cycles suggest anovulation; regular cycles make structural causes more likely |
| Normal menstrual flow | “How heavy are your normal periods? How many days do they last?” | Baseline for comparison; heavy menses with intermenstrual bleeding suggests fibroids |
| Menarche and menstrual history | “At what age did you start your periods? Have you ever had irregular bleeding before?” | Early menarche increases estrogen exposure; history of irregularity suggests chronic issue |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Pregnancy-related | Missed period, breast tenderness, nausea, unprotected intercourse | “Is there any possibility you could be pregnant? Have you had unprotected intercourse?” |
| Ectopic pregnancy | Unilateral pelvic pain, vaginal bleeding, positive pregnancy test | “Do you have pain on one side of your pelvis? Any shoulder tip pain or dizziness?” |
| Hormonal contraceptive breakthrough | Recent start or change of contraception, missed pills | “Have you recently started or changed your contraceptive? Have you missed any pills?” |
| Ovulation bleeding | Predictable mid-cycle spotting, mild pelvic discomfort | “Does the spotting happen around the middle of your cycle each month? Any cramping at the same time?” |
| Endometrial polyps | Irregular spotting, may be postcoital, often in perimenopausal women | “Is the bleeding unpredictable? Does it happen after intercourse?” |
| Uterine fibroids | Heavy periods with intermenstrual spotting, pelvic pressure, urinary frequency | “Are your periods heavier than they used to be? Do you feel pressure in your pelvis or need to urinate frequently?” |
| Cervical ectropion or pathology | Postcoital bleeding, increased vaginal discharge | “Does bleeding occur after intercourse? Have you noticed increased vaginal discharge?” |
| Cervical cancer | Postcoital bleeding, foul discharge, risk factors (smoking, HPV, no screening) | “When was your last cervical smear? Have you ever had an abnormal smear result?” |
| Endometrial cancer/hyperplasia | Postmenopausal bleeding, obesity, unopposed estrogen, diabetes | “Have you experienced any bleeding after menopause? Do you have diabetes or high blood pressure?” |
| Infection (cervicitis, endometritis, pelvic inflammatory disease) | Abnormal discharge, pelvic pain, fever, dyspareunia | “Do you have any unusual vaginal discharge? Any pain during intercourse or pelvic pain?” |
| Coagulopathy | Easy bruising, prolonged bleeding from cuts, heavy periods since menarche, family history | “Do you bruise easily? Do cuts take a long time to stop bleeding? Have your periods always been very heavy?” |
| Intrauterine device-related | Bleeding following insertion, irregular spotting (especially with hormonal intrauterine device) | “Do you have an intrauterine device? When was it inserted? Can you feel the strings?” |
Sexual and Reproductive History
Sexual History
- Sexual activity: Currently sexually active? New partner?
- Contraception: Type, duration, compliance
- Postcoital bleeding: Does bleeding occur after intercourse?
- Dyspareunia: Pain during intercourse (suggests infection, endometriosis)
- Sexually transmitted infection risk: Multiple partners, unprotected intercourse, previous infections
Reproductive History
- Gravidity and parity: Previous pregnancies, outcomes
- Pregnancy intentions: Trying to conceive? Recent pregnancy?
- Previous gynecological procedures: Dilatation and curettage, cone biopsy, loop excision
- Fertility issues: History of infertility, recurrent pregnancy loss (suggests chronic endometritis)
- Cervical screening history: Last smear, previous abnormal results, colposcopy
Medication and Iatrogenic Causes
Medications That Cause Intermenstrual Bleeding
- Combined oral contraceptives — Breakthrough bleeding, especially in first 3 months or with missed pills
- Progestin-only contraceptives — Irregular bleeding is common and expected (pills, implant, injection, hormonal intrauterine device)
- Anticoagulants — Warfarin, direct oral anticoagulants, heparin increase bleeding
- Antiplatelet agents — Aspirin, clopidogrel
- Selective serotonin reuptake inhibitors (SSRIs) — Impair platelet function
- Hormone replacement therapy — Breakthrough bleeding, especially in early use
- Tamoxifen — Increases endometrial polyps, hyperplasia, cancer risk
- Corticosteroids — Long-term use affects menstrual cycle
- Herbal supplements — Ginseng, soy, black cohosh have estrogenic effects
Questions About Medications
- “What medications are you currently taking, including over-the-counter and supplements?”
- “Have you recently started any new medications?”
- “Are you taking any blood thinners?”
- “What type of contraception do you use? How long have you been using it?”
- “Have you missed any contraceptive pills recently?”
- “Have you recently changed your contraceptive method or dose?”
- “Are you taking any herbal remedies or supplements?”
Past Medical and Family History
Past Medical History
- Gynecological conditions: Known fibroids, polyps, endometriosis, polycystic ovary syndrome
- Previous gynecological surgery: Myomectomy, polypectomy, hysteroscopy, cone biopsy
- Bleeding disorders: Von Willebrand disease, platelet disorders, clotting factor deficiencies
- Thyroid disease: Both hypothyroidism and hyperthyroidism affect menstruation
- Liver disease: Impairs estrogen metabolism and clotting factor production
- Chronic conditions: Diabetes, obesity, hypertension (endometrial cancer risk factors)
Family History
- Bleeding disorders: Von Willebrand disease, hemophilia (suggests inherited coagulopathy)
- Gynecological cancers: Endometrial, ovarian, cervical, breast cancer
- Lynch syndrome: Family history of colorectal, endometrial, ovarian cancers at young age
- Uterine fibroids: Tend to run in families, especially in women of African descent
- Polycystic ovary syndrome: May have familial clustering
Social and Lifestyle History
| Factor | Relevance | What to Ask |
|---|---|---|
| Smoking | Risk factor for cervical cancer and dysplasia; affects estrogen metabolism; reduces contraceptive efficacy | “Do you smoke? How many cigarettes per day?” |
| Alcohol | Affects liver function and estrogen metabolism; heavy use associated with menstrual irregularities | “How much alcohol do you drink per week?” |
| Body weight | Obesity increases estrogen through peripheral conversion; risk factor for anovulation and endometrial cancer | “Has your weight changed significantly recently?” |
| Stress and exercise | Extreme stress or exercise can cause anovulation and irregular bleeding | “Have you been under significant stress? Do you exercise intensively?” |
| Occupation | Shift work can disrupt menstrual cycles; some occupations have chemical exposures | “What is your occupation? Do you work shifts?” |
4. Physical Examination
A systematic approach for evaluating intermenstrual bleeding
Systematic Framework: Use a “General to Specific” approach — begin with general assessment and vital signs, then proceed to abdominal examination, and finally pelvic examination. Always ensure privacy, obtain consent, offer a chaperone, and explain each step to the patient.
General Inspection
- Appearance and body habitus: Obesity (endometrial cancer risk, anovulation), cachexia (malignancy), hirsutism and acne (polycystic ovary syndrome)
- Signs of anemia: Pallor of conjunctivae, mucous membranes, nail beds (suggests chronic or heavy blood loss)
- Signs of bleeding disorder: Petechiae, ecchymoses, bruising (coagulopathy)
- Thyroid: Goiter, exophthalmos, tremor, bradycardia (thyroid dysfunction affects menstruation)
- Signs of hyperandrogenism: Hirsutism, acne, male-pattern hair loss (polycystic ovary syndrome, androgen-secreting tumor)
- Acanthosis nigricans: Velvety hyperpigmentation in skin folds (insulin resistance, polycystic ovary syndrome)
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart rate | Tachycardia (greater than 100 beats per minute) | May indicate significant blood loss, anemia, infection, ectopic pregnancy with hemorrhage |
| Blood pressure | Hypotension, orthostatic changes | Suggests hemodynamic compromise from blood loss; urgent intervention needed |
| Temperature | Fever (greater than 38°C) | Suggests infection: pelvic inflammatory disease, endometritis, septic abortion |
| Respiratory rate | Tachypnea | May indicate anemia, metabolic acidosis from significant hemorrhage |
| Body mass index | Obesity (BMI greater than 30) or underweight (BMI less than 18.5) | Obesity: anovulation, endometrial cancer risk; underweight: hypothalamic amenorrhea |
Abdominal Examination
Inspection
- Distension: May indicate large fibroid uterus, ascites (ovarian malignancy), pregnancy
- Visible masses: Large fibroids may be visible as lower abdominal bulge
- Surgical scars: Previous cesarean section, laparoscopy, laparotomy
- Striae: May indicate rapid weight changes, Cushing syndrome
Palpation
- Tenderness: Suprapubic tenderness (infection, ectopic pregnancy), rebound tenderness (peritonitis)
- Masses: Palpable uterus (fibroids, pregnancy beyond 12 weeks), adnexal masses
- Guarding and rigidity: Suggests peritoneal irritation (ruptured ectopic, tubo-ovarian abscess)
- Hepatomegaly: Liver disease affecting estrogen metabolism and coagulation
- Lymphadenopathy: Inguinal lymph nodes (infection, malignancy)
Percussion and Auscultation
- Shifting dullness: Ascites may indicate ovarian malignancy
- Bowel sounds: Absent or hypoactive in peritonitis
Pelvic Examination
Before Proceeding
Ensure the patient has emptied her bladder. Obtain informed consent and offer a chaperone. Position the patient in lithotomy or left lateral position. Ensure adequate lighting and warm speculum. Explain each step before performing it.
External Genital Inspection
- Vulva: Lesions, ulcers, warts, atrophy, excoriation, signs of trauma
- Urethral meatus: Caruncle, prolapse, discharge (urethral source of bleeding)
- Vaginal introitus: Bleeding, discharge, lesions, atrophy
- Perineum and perianal area: Hemorrhoids, fissures (rectal source of bleeding)
Speculum Examination
| Structure | What to Assess | Abnormal Findings and Their Significance |
|---|---|---|
| Vaginal walls | Color, lesions, discharge, foreign bodies, atrophy | Atrophy (hypoestrogenic state), lesions (trauma, malignancy), retained tampon or foreign body |
| Cervix | Position, size, shape, surface, os | Ectropion (red granular area around os), polyps protruding from os, nabothian cysts, contact bleeding |
| Cervical lesions | Ulceration, mass, friable tissue, bleeding on touch | Visible mass suggests cervical cancer; friability may indicate infection, dysplasia, or malignancy |
| Cervical os | Open or closed, products of conception, polyps | Open os with products of conception (inevitable/incomplete miscarriage); polyp visible at os |
| Discharge | Color, consistency, odor | Purulent (infection), blood-stained (cervical pathology), foul-smelling (bacterial vaginosis, malignancy) |
| Intrauterine device strings | Visible and appropriate length | Missing strings may indicate expulsion, perforation, or pregnancy |
| Active bleeding | Source: cervical os, cervical surface, vaginal walls | Identify the source of bleeding; blood coming from os suggests uterine source |
Cervical Examination Technique
Carefully inspect the entire cervix by rotating the speculum. Note the transformation zone (junction between squamous and columnar epithelium). Use a swab to gently clear blood or discharge to visualize the cervix properly. If a lesion is seen, do not take a smear — instead, refer urgently for colposcopy. Take swabs for infection screening (chlamydia, gonorrhea) if indicated.
Bimanual Examination
| Structure | What to Assess | Abnormal Findings |
|---|---|---|
| Cervix | Position, consistency, mobility, tenderness | Cervical motion tenderness (pelvic inflammatory disease, ectopic pregnancy); fixed cervix (malignancy, endometriosis) |
| Uterus — size | Normal size is approximately 8 cm (size of a small pear) | Enlarged: fibroids (irregular, firm), adenomyosis (globular, tender), pregnancy |
| Uterus — contour | Regular or irregular | Irregular contour suggests fibroids; smooth enlargement suggests adenomyosis or pregnancy |
| Uterus — mobility | Mobile or fixed | Fixed uterus suggests endometriosis, adhesions, or malignancy with parametrial involvement |
| Uterus — tenderness | Tenderness on palpation | Tender uterus suggests infection (endometritis), adenomyosis, or pregnancy complication |
| Adnexa | Masses, tenderness | Adnexal mass (ovarian cyst, ectopic pregnancy, tubo-ovarian abscess); tenderness (infection, ectopic) |
| Pouch of Douglas | Nodularity, tenderness, fullness | Nodularity (endometriosis); fullness and tenderness (blood, pus, or fluid collection) |
Expected Findings by Etiology
| Condition | General Examination | Abdominal Examination | Pelvic Examination |
|---|---|---|---|
| Cervical ectropion | Usually normal | Normal | Red, granular area around cervical os; bleeds easily on contact |
| Cervical polyp | Usually normal | Normal | Smooth, red polyp protruding from cervical os |
| Cervical cancer | May have cachexia, lymphadenopathy in advanced cases | Usually normal; may have inguinal lymphadenopathy | Visible cervical lesion (ulcer, mass, friable tissue); contact bleeding; fixed cervix in advanced disease |
| Uterine fibroids | Usually normal; may have pallor if anemic | May have palpable mass arising from pelvis | Enlarged, irregular, firm, mobile uterus; submucous fibroid may be visible at os |
| Endometrial polyp | Usually normal | Normal | Usually normal; occasionally polyp protrudes through cervical os |
| Endometrial cancer | May be obese; pallor if anemic | Usually normal | Often normal; may have blood at os; enlarged uterus in advanced disease |
| Pelvic inflammatory disease | May appear unwell, febrile | Lower abdominal tenderness, guarding | Purulent discharge, cervical motion tenderness, adnexal tenderness, possible adnexal mass |
| Ectopic pregnancy | May be pale, tachycardic, hypotensive | Lower abdominal tenderness, guarding if ruptured | Cervical motion tenderness, adnexal tenderness or mass, uterus may be slightly enlarged |
| Hormonal contraceptive breakthrough | Normal | Normal | Normal; intrauterine device strings visible if present |
| Polycystic ovary syndrome | Obesity, hirsutism, acne, acanthosis nigricans | Central adiposity | Usually normal; may have enlarged ovaries |
| Coagulopathy | Petechiae, ecchymoses, bruising | Hepatosplenomegaly in some conditions | Usually normal |
Important Teaching Point
Normal examination is common! Many causes of intermenstrual bleeding present with entirely normal physical examination findings. This includes endometrial polyps (unless protruding), small fibroids, hormonal breakthrough bleeding, ovulation bleeding, chronic endometritis, and early endometrial pathology. A normal examination does not exclude significant pathology and should not prevent further investigation — particularly in women over 40, those with persistent symptoms, or those with risk factors for malignancy. Transvaginal ultrasound and/or endometrial biopsy may be required even when examination is unremarkable.
5. Differential Diagnosis
Systematic approach organized by probability, age, and clinical features
The differential diagnosis of intermenstrual bleeding is broad and varies significantly by age, reproductive status, and clinical context. A systematic approach using the FIGO PALM-COEIN classification helps ensure no important cause is overlooked. Always consider pregnancy first in any woman of reproductive age.
Step-by-Step Approach to Intermenstrual Bleeding:
- Step 1: Rule out pregnancy — obtain β-hCG in all reproductive-age women
- Step 2: Identify red flags requiring urgent evaluation (hemodynamic instability, postmenopausal bleeding, suspicious cervical lesion)
- Step 3: Consider the patient’s age and menopausal status — this significantly changes the differential
- Step 4: Review medications and contraceptive use — iatrogenic causes are very common
- Step 5: Apply the PALM-COEIN framework to systematically consider structural and non-structural causes
Reproductive Age Women (18-40 years)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 60-70%) | Hormonal contraceptive breakthrough bleeding | Recent start or change of contraception, missed pills, first 3 months of use | None typically; exclude pregnancy if pills missed |
| COMMON | Ovulation bleeding (mittelschmerz) | Predictable mid-cycle spotting, mild unilateral pelvic discomfort, light and brief | None — physiological |
| COMMON | Cervical ectropion | Postcoital bleeding, increased discharge, visible red area around cervical os | Must exclude cervical dysplasia/cancer |
| COMMON | Pregnancy-related (implantation, threatened miscarriage) | Positive pregnancy test, light spotting, may have cramping | Heavy bleeding, severe pain, hemodynamic instability |
| LESS COMMON (approximately 20-30%) | Endometrial polyps | Irregular spotting, postcoital bleeding, may be asymptomatic | Postmenopausal; risk of malignant change |
| LESS COMMON | Uterine fibroids (leiomyomas) | Heavy periods, intermenstrual bleeding, pelvic pressure, enlarged irregular uterus | Rapid growth, postmenopausal growth |
| LESS COMMON | Cervicitis and sexually transmitted infections | Abnormal discharge, postcoital bleeding, dyspareunia, pelvic pain | Fever, severe pelvic pain (pelvic inflammatory disease) |
| LESS COMMON | Cervical polyps | Postcoital bleeding, visible polyp at cervical os | Usually benign but should be removed and sent for histology |
| LESS COMMON | Ectopic pregnancy | Unilateral pelvic pain, vaginal bleeding, positive pregnancy test | Hemodynamic instability, shoulder tip pain — surgical emergency |
| UNCOMMON BUT SERIOUS (approximately 5-10%) | Cervical intraepithelial neoplasia or cervical cancer | Postcoital bleeding, abnormal discharge, visible cervical lesion | Friable cervical mass, foul discharge, weight loss |
| UNCOMMON BUT SERIOUS | Coagulopathy (von Willebrand disease, platelet disorders) | Heavy periods since menarche, easy bruising, family history | Severe bleeding, other bleeding manifestations |
| UNCOMMON BUT SERIOUS | Chronic endometritis | Subtle irregular bleeding, infertility, history of pelvic inflammatory disease or intrauterine procedures | Associated infertility, recurrent pregnancy loss |
Perimenopausal Women (40-50 years)
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Anovulatory bleeding (dysfunctional uterine bleeding) | 30-40% | Irregular cycles, variable flow, no structural abnormality on imaging |
| COMMON | Endometrial polyps | 20-30% | Irregular spotting, visible on ultrasound or hysteroscopy |
| COMMON | Uterine fibroids | 20-30% | Heavy periods, enlarged uterus, may have pressure symptoms |
| LESS COMMON | Adenomyosis | 10-15% | Dysmenorrhea, heavy bleeding, globular tender uterus |
| LESS COMMON | Endometrial hyperplasia | 5-10% | Obesity, anovulation, thickened endometrium on ultrasound |
| UNCOMMON BUT MUST EXCLUDE | Endometrial carcinoma | 1-5% | Risk factors (obesity, diabetes, nulliparity, tamoxifen), persistent bleeding |
| UNCOMMON BUT MUST EXCLUDE | Cervical carcinoma | 1-2% | Postcoital bleeding, abnormal cervix on examination, overdue screening |
Postmenopausal Women (over 50 years or more than 12 months since last period)
Critical Principle
All postmenopausal bleeding must be considered endometrial cancer until proven otherwise. Approximately 10% of postmenopausal bleeding is due to endometrial cancer. All women with postmenopausal bleeding require investigation including transvaginal ultrasound and consideration of endometrial biopsy.
| Probability | Condition | Approximate Frequency | Key Features |
|---|---|---|---|
| COMMON | Atrophic vaginitis | 30-40% | Thin, pale vaginal epithelium; spotting, dyspareunia, discharge |
| COMMON | Endometrial atrophy | 20-30% | Thin endometrium (less than 4 mm) on ultrasound, scant bleeding |
| LESS COMMON | Endometrial polyps | 10-20% | Focal thickening on ultrasound, may be seen on saline infusion sonography |
| LESS COMMON | Hormone replacement therapy-related bleeding | 10-15% | Temporal relationship with hormone therapy use |
| MUST EXCLUDE | Endometrial carcinoma | 5-10% | Thickened endometrium (greater than 4 mm), risk factors |
| MUST EXCLUDE | Endometrial hyperplasia | 5-10% | Precursor to carcinoma; requires histological diagnosis |
| UNCOMMON | Cervical carcinoma | 1-2% | Abnormal cervical appearance, contact bleeding |
Anatomical Approach to Differential Diagnosis
Uterine Corpus
Endometrial polyps
Submucosal fibroids
Adenomyosis
Endometrial hyperplasia
Endometrial carcinoma
Chronic endometritis
Intrauterine device-related
Arteriovenous malformation
Cervix
Cervical ectropion
Cervical polyps
Cervicitis
Cervical intraepithelial neoplasia
Cervical carcinoma
Cervical trauma
Nabothian cysts (rarely bleed)
Vagina and Vulva
Atrophic vaginitis
Vaginal trauma
Vaginal infection
Vaginal cancer (rare)
Foreign body
Vulvar lesions
Systemic and Hormonal
Anovulatory bleeding
Coagulopathy
Thyroid dysfunction
Hyperprolactinemia
Polycystic ovary syndrome
Medication-induced
Pregnancy-related
FIGO PALM-COEIN Classification
| Category | Cause | Key Features | Primary Investigation |
|---|---|---|---|
| PALM (Structural) | Polyp (endometrial or cervical) | Irregular bleeding, postcoital, visible on imaging or examination | Transvaginal ultrasound, saline infusion sonography, hysteroscopy |
| Adenomyosis | Dysmenorrhea, heavy bleeding, globular tender uterus | Transvaginal ultrasound, MRI | |
| Leiomyoma (fibroid) | Heavy periods, pressure symptoms, enlarged irregular uterus | Transvaginal ultrasound | |
| Malignancy and hyperplasia | Risk factors, persistent bleeding, postmenopausal bleeding | Endometrial biopsy, hysteroscopy | |
| COEIN (Non-structural) | Coagulopathy | Heavy bleeding since menarche, bruising, family history | Complete blood count, coagulation studies, von Willebrand panel |
| Ovulatory dysfunction | Irregular cycles, features of polycystic ovary syndrome, perimenopausal | Hormone levels (follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone) | |
| Endometrial (primary disorder) | Diagnosis of exclusion, may have chronic endometritis | Endometrial biopsy | |
| Iatrogenic | Hormonal contraceptives, anticoagulants, hormone replacement therapy | Medication review | |
| Not yet classified | Rare causes, arteriovenous malformation, myometrial hypertrophy | Advanced imaging, specialist referral |
Drug-Induced Intermenstrual Bleeding
| Drug or Drug Class | Mechanism | Characteristics | Management |
|---|---|---|---|
| Combined oral contraceptives | Inadequate estrogen for endometrial stability; missed pills cause hormone withdrawal | Common in first 3 months; light spotting; related to missed pills | Reassurance if new; consider higher estrogen formulation if persistent; exclude other causes |
| Progestin-only pills | Atrophic, fragile endometrium without estrogen support | Irregular spotting common and expected; unpredictable pattern | Counseling; may improve over time; consider alternative method if unacceptable |
| Levonorgestrel intrauterine device | Local progestin effect causing endometrial atrophy | Irregular spotting common in first 3-6 months; usually decreases over time | Reassurance; bleeding typically improves; exclude malposition or infection |
| Copper intrauterine device | Local inflammatory response; no hormonal effect | Heavier periods; intermenstrual spotting less common than with hormonal intrauterine device | Rule out malposition, infection, or expulsion |
| Depot medroxyprogesterone acetate (injection) | Continuous progestin causing endometrial atrophy | Irregular bleeding common initially; may progress to amenorrhea | Counseling; bleeding often improves with continued use |
| Etonogestrel implant | Continuous progestin causing variable endometrial effects | Unpredictable bleeding pattern; most common reason for discontinuation | Counseling; short course of combined pill may help |
| Anticoagulants (warfarin, direct oral anticoagulants, heparin) | Impaired hemostasis allows bleeding from minor endometrial disruption | May unmask underlying pathology; heavier and prolonged bleeding | Investigate for underlying cause; liaise with anticoagulation service |
| Antiplatelet agents (aspirin, clopidogrel) | Impaired platelet function | May increase bleeding from any cause | Investigate for underlying pathology |
| Selective serotonin reuptake inhibitors | Impair platelet aggregation via serotonin effects | May increase menstrual and intermenstrual bleeding | Consider if temporal relationship; investigate other causes |
| Tamoxifen | Partial estrogen agonist effect on endometrium; increases polyps, hyperplasia, cancer risk | Any bleeding on tamoxifen requires investigation | Transvaginal ultrasound and endometrial biopsy mandatory |
| Hormone replacement therapy | Endometrial stimulation; breakthrough bleeding with continuous regimens | Unscheduled bleeding on hormone replacement therapy needs evaluation | Investigate to exclude endometrial pathology |
| Corticosteroids (chronic use) | Affects hypothalamic-pituitary-ovarian axis | Menstrual irregularity, anovulation | Address underlying condition requiring steroids |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Positive pregnancy test with bleeding | Threatened miscarriage, ectopic pregnancy | Urgent transvaginal ultrasound, serial β-hCG |
| Postmenopausal bleeding | Endometrial cancer until proven otherwise | Transvaginal ultrasound, endometrial biopsy |
| Postcoital bleeding with visible cervical lesion | Cervical cancer | Urgent colposcopy referral (do not take smear) |
| Mid-cycle spotting, predictable each month | Ovulation bleeding (physiological) | Reassurance if pattern consistent; consider ultrasound if uncertain |
| Bleeding after starting new contraceptive | Breakthrough bleeding (iatrogenic) | Reassurance; review in 3 months; exclude missed pills |
| Heavy periods with intermenstrual bleeding, enlarged uterus | Uterine fibroids | Transvaginal ultrasound |
| Irregular bleeding with obesity, hirsutism, irregular cycles | Polycystic ovary syndrome with anovulation | Hormone levels, ultrasound, consider endometrial protection |
| Purulent discharge, pelvic pain, cervical motion tenderness | Pelvic inflammatory disease | Swabs for infection, empiric antibiotics |
| Heavy bleeding since menarche, easy bruising | Coagulopathy (von Willebrand disease) | Coagulation studies, von Willebrand panel, hematology referral |
| Bleeding on tamoxifen | Endometrial pathology (polyp, hyperplasia, cancer) | Mandatory transvaginal ultrasound and endometrial biopsy |
| Unexplained bleeding with infertility history | Chronic endometritis | Endometrial biopsy looking for plasma cells |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
Investigation of intermenstrual bleeding should be tailored to the patient’s age, risk factors, and clinical presentation. A stepwise approach beginning with basic investigations and progressing to more specialized tests based on initial findings is most cost-effective.
First-Line Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Urine or serum β-hCG | Exclude pregnancy | Positive result requires pregnancy-related workup | Mandatory in all reproductive-age women regardless of contraceptive use or stated sexual activity |
| Complete blood count | Assess for anemia, thrombocytopenia | Hemoglobin less than 120 g/L (anemia); low platelets (bleeding risk) | Guides need for iron supplementation; severe anemia may need transfusion |
| Cervical screening (if due) | Screen for cervical dysplasia or cancer | Abnormal cytology or positive high-risk HPV | Do NOT take smear if visible cervical lesion — refer directly for colposcopy |
| Infection screening | Detect sexually transmitted infections | Chlamydia, gonorrhea (nucleic acid amplification test) | Offer to all sexually active women; treat partners if positive |
| Transvaginal ultrasound | Assess uterine and ovarian structure | Endometrial thickness, polyps, fibroids, ovarian pathology | First-line imaging; best performed in proliferative phase (days 5-10) for endometrial assessment |
Transvaginal Ultrasound: Key Findings and Interpretation
| Finding | Normal Values | Abnormal Findings | Clinical Significance |
|---|---|---|---|
| Endometrial thickness (premenopausal) | Varies with cycle: 2-4 mm (menstrual), up to 14 mm (secretory) | Thickened, irregular, or heterogeneous endometrium | Consider polyp, hyperplasia, or malignancy if abnormal |
| Endometrial thickness (postmenopausal) | Less than or equal to 4 mm (not on hormone replacement therapy) | Greater than 4 mm or any focal thickening | Requires endometrial sampling to exclude malignancy |
| Endometrial polyp | None | Focal echogenic lesion within endometrial cavity, often with feeding vessel on Doppler | Hysteroscopic removal recommended for diagnosis and treatment |
| Uterine fibroids | None | Well-defined hypoechoic masses; note location (submucosal, intramural, subserosal) | Submucosal fibroids most likely to cause intermenstrual bleeding |
| Adenomyosis | Homogeneous myometrium | Heterogeneous myometrium, asymmetric wall thickening, myometrial cysts, poor definition of endometrial-myometrial junction | May coexist with fibroids; MRI more accurate if diagnosis uncertain |
| Intrauterine device position | Fundal position | Low-lying, embedded, or absent | Malposition may cause bleeding; absent device needs plain radiograph to distinguish expulsion from perforation |
Targeted Investigations by Clinical Suspicion
If Suspecting Endometrial Pathology (Polyp, Hyperplasia, Malignancy)
First-Line Tests
- Transvaginal ultrasound: Endometrial thickness greater than 4 mm postmenopausal, focal lesions, heterogeneous endometrium
- Endometrial biopsy (Pipelle): Outpatient sampling; sensitivity approximately 90% for endometrial cancer in postmenopausal women
Second-Line Tests
- Saline infusion sonohysterography: Better visualization of focal lesions (polyps, submucosal fibroids)
- Hysteroscopy with directed biopsy: Gold standard for diagnosing and treating intrauterine pathology; can remove polyps
If Suspecting Cervical Pathology
First-Line Tests
- Speculum examination: Visualize cervix for ectropion, polyps, lesions
- Cervical smear: If no visible lesion and screening is due
- Infection screening: Chlamydia and gonorrhea nucleic acid amplification test
Second-Line Tests
- Colposcopy: If abnormal smear, visible lesion, or persistent postcoital bleeding; allows directed biopsy
- Cervical biopsy: If suspicious lesion seen — do NOT take smear, refer directly
If Suspecting Pregnancy-Related Cause
First-Line Tests
- Serum β-hCG: Quantitative level helps assess pregnancy viability and location
- Transvaginal ultrasound: Locate pregnancy (intrauterine versus extrauterine), assess viability
Second-Line Tests
- Serial β-hCG (48-72 hours): Doubling time helps assess viability; slower rise suggests ectopic or failing pregnancy
- Progesterone level: Low progesterone (less than 25 nmol/L) associated with non-viable pregnancy
If Suspecting Hormonal or Ovulatory Dysfunction
First-Line Tests
- Day 21 progesterone: Greater than 30 nmol/L confirms ovulation; low level suggests anovulation
- Thyroid function tests: Both hypothyroidism and hyperthyroidism cause menstrual irregularity
- Prolactin: Elevated prolactin causes anovulation
Second-Line Tests
- Follicle-stimulating hormone and luteinizing hormone: High follicle-stimulating hormone suggests ovarian insufficiency; high luteinizing hormone-to-follicle-stimulating hormone ratio suggests polycystic ovary syndrome
- Androgens (testosterone, sex hormone-binding globulin): If polycystic ovary syndrome suspected
- Anti-Müllerian hormone: Ovarian reserve assessment
If Suspecting Coagulopathy
First-Line Tests
- Complete blood count: Platelet count; mean platelet volume
- Coagulation studies: Prothrombin time, activated partial thromboplastin time
Second-Line Tests
- Von Willebrand factor antigen and activity: Von Willebrand disease is most common inherited bleeding disorder
- Factor VIII level: Often reduced in von Willebrand disease
- Platelet function tests: If platelet count normal but bleeding symptoms persist
Endometrial Biopsy: When Is It Indicated?
Indications for Endometrial Sampling
- All postmenopausal bleeding — regardless of endometrial thickness
- Endometrial thickness greater than 4 mm postmenopausal — on transvaginal ultrasound
- Women over 45 with abnormal bleeding — to exclude malignancy
- Women under 45 with risk factors: obesity, diabetes, polycystic ovary syndrome, chronic anovulation, tamoxifen use, family history of Lynch syndrome
- Persistent intermenstrual bleeding — despite normal ultrasound, especially if age over 40
- Failed medical management — of abnormal bleeding
- Any bleeding on tamoxifen — mandatory investigation
| Biopsy Method | Setting | Advantages | Limitations |
|---|---|---|---|
| Pipelle endometrial biopsy | Outpatient, office-based | Quick, inexpensive, no anesthesia, high sensitivity for diffuse pathology | Blind sampling may miss focal lesions (polyps); insufficient sample in 10-15% |
| Hysteroscopy with directed biopsy | Outpatient or operating theater | Direct visualization, can biopsy specific lesions, therapeutic (polyp removal) | More invasive, requires equipment and expertise, higher cost |
| Dilatation and curettage | Operating theater, general anesthesia | Comprehensive sampling | Blind procedure, may miss focal lesions, largely replaced by hysteroscopy |
Investigation Strategy by Age Group
| Age Group | Mandatory Investigations | Consider Adding | Key Concern |
|---|---|---|---|
| Under 40 years | Pregnancy test, infection screening, transvaginal ultrasound if persistent | Hormones if anovulation suspected; coagulation if heavy bleeding since menarche | Pregnancy-related causes, contraceptive issues, infections |
| 40-45 years | Pregnancy test, transvaginal ultrasound, cervical screening | Endometrial biopsy if risk factors or persistent bleeding | Increasing structural pathology risk; consider malignancy if risk factors |
| Over 45 years (premenopausal) | Pregnancy test, transvaginal ultrasound, endometrial biopsy | Hysteroscopy if focal pathology suspected | Malignancy must be excluded; structural causes common |
| Postmenopausal | Transvaginal ultrasound, endometrial biopsy | Hysteroscopy if endometrium thickened or sampling inadequate | Endometrial cancer — 10% of postmenopausal bleeding |
When to Refer to Specialist
Urgent Referral Indications
- Suspected cervical cancer: Visible cervical lesion, especially friable or bleeding on contact
- Postmenopausal bleeding with thickened endometrium: Greater than 4 mm or unable to visualize
- Abnormal endometrial biopsy: Hyperplasia with atypia, suspected malignancy
- Suspected ectopic pregnancy: Positive β-hCG with no intrauterine pregnancy, adnexal mass, or pain
- Persistent bleeding despite treatment: Requires further investigation
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for intermenstrual bleeding
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Heavy bleeding with hemodynamic instability (tachycardia, hypotension, pallor) | EMERGENT | Resuscitate (IV access, fluids, blood products), urgent gynecology consultation, consider surgical intervention |
| Positive pregnancy test with bleeding and abdominal pain | EMERGENT | Exclude ectopic pregnancy — urgent transvaginal ultrasound, serum β-hCG, prepare for possible surgery |
| Postmenopausal bleeding | URGENT | Arrange transvaginal ultrasound within 2 weeks, endometrial biopsy, fast-track referral pathway |
| Visible suspicious cervical lesion | URGENT | Urgent colposcopy referral (within 2 weeks); do NOT take cervical smear — refer directly |
| Intermenstrual bleeding with pelvic pain and fever | URGENT | Consider pelvic inflammatory disease or septic abortion; take swabs, start empiric antibiotics, consider admission |
| New intermenstrual bleeding in woman over 40 | URGENT | Arrange transvaginal ultrasound; consider endometrial biopsy; gynecology referral if abnormal |
| Persistent postcoital bleeding | URGENT | Speculum examination, cervical screening if due, colposcopy referral if cervix abnormal or bleeding persists |
| Breakthrough bleeding on new contraceptive (less than 3 months) | ROUTINE | Reassurance, ensure compliance, exclude pregnancy if pills missed, review in 3 months |
| Mid-cycle spotting, predictable pattern, young woman | ROUTINE | Likely ovulation bleeding; reassurance; investigate if pattern changes or becomes heavy |
Step 2: Initial Assessment Algorithm
First Questions to Answer:
- Is she pregnant? → Perform β-hCG test in ALL reproductive-age women
- Is she hemodynamically stable? → Check vital signs; resuscitate if unstable
- Is she postmenopausal? → If yes, investigate urgently for malignancy
- Is there a visible cervical abnormality? → If suspicious lesion, urgent colposcopy referral
- Is she on medications that cause bleeding? → Review contraceptives, anticoagulants
Step 3: Algorithm Based on Pregnancy Status
Algorithm A: Pregnancy Test Positive
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Light spotting, no pain, closed cervix | Threatened miscarriage or implantation bleeding | Transvaginal ultrasound to confirm viability and location; serial β-hCG if too early to see pregnancy |
| Bleeding with cramping, open cervix, products visible | Inevitable or incomplete miscarriage | Options: expectant, medical (misoprostol), or surgical management; support and follow-up |
| Unilateral pelvic pain, bleeding, positive β-hCG, no intrauterine pregnancy on ultrasound | Ectopic pregnancy until proven otherwise | Urgent gynecology review; serial β-hCG; prepare for possible surgical or medical management |
| Bleeding, very high β-hCG, “snowstorm” appearance on ultrasound | Gestational trophoblastic disease | Specialist referral to gestational trophoblastic disease center; chest radiograph; arrange management |
Algorithm B: Pregnancy Test Negative — Premenopausal Woman
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Recently started hormonal contraceptive (less than 3 months) | Breakthrough bleeding (iatrogenic) | Reassurance; review compliance; review in 3 months; consider alternative formulation if persistent |
| Missed contraceptive pills | Estrogen withdrawal bleeding | Advise on correct pill-taking; emergency contraception if unprotected intercourse; exclude pregnancy |
| Predictable mid-cycle light spotting with mild pelvic discomfort | Ovulation bleeding (physiological) | Reassurance; no investigation needed if pattern consistent and patient reassured |
| Postcoital bleeding, red granular area around cervical os | Cervical ectropion | Reassurance; ensure cervical screening up to date; treat with cryotherapy or cautery if troublesome |
| Postcoital bleeding, abnormal cervical appearance | Cervical pathology (dysplasia or cancer) | Urgent colposcopy referral; do NOT take smear if suspicious lesion visible |
| Irregular bleeding, purulent discharge, pelvic pain, cervical motion tenderness | Pelvic inflammatory disease | Swabs for chlamydia and gonorrhea; empiric antibiotics; partner notification; consider admission if severe |
| Irregular bleeding, enlarged irregular uterus, heavy periods | Uterine fibroids | Transvaginal ultrasound; consider referral for management if symptomatic |
| Irregular bleeding, normal examination, ultrasound shows focal endometrial lesion | Endometrial polyp | Hysteroscopy for diagnosis and polypectomy |
| Irregular bleeding, obesity, hirsutism, irregular cycles, polycystic ovaries | Polycystic ovary syndrome with anovulation | Hormonal management (combined pill, cyclical progestogens); weight management; consider endometrial protection |
Algorithm C: Pregnancy Test Negative — Postmenopausal Woman
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Thin atrophic vaginal epithelium, spotting, dyspareunia | Atrophic vaginitis | Vaginal estrogen therapy; still requires transvaginal ultrasound to exclude endometrial pathology |
| Endometrial thickness less than or equal to 4 mm on transvaginal ultrasound | Atrophic endometrium (low malignancy risk) | Reassurance if single episode; consider biopsy if recurrent; treat atrophic vaginitis if present |
| Endometrial thickness greater than 4 mm on transvaginal ultrasound | Endometrial pathology — polyp, hyperplasia, or carcinoma | Endometrial biopsy mandatory; consider hysteroscopy for focal lesions |
| Focal endometrial lesion on ultrasound | Endometrial polyp (most likely) or focal pathology | Hysteroscopy with polypectomy and histology |
| Thickened heterogeneous endometrium, risk factors (obesity, diabetes) | Endometrial hyperplasia or carcinoma | Urgent endometrial biopsy; gynecology oncology referral if malignancy confirmed |
| On hormone replacement therapy with unscheduled bleeding | Breakthrough bleeding, but must exclude pathology | Transvaginal ultrasound; endometrial biopsy if endometrium thickened or bleeding persists |
| On tamoxifen with any bleeding | High risk of endometrial pathology (polyp, hyperplasia, cancer) | Mandatory transvaginal ultrasound and endometrial biopsy |
Step 4: Age-Based Decision Framework
Under 40 Years
Primary concerns: Pregnancy, contraceptive issues, infections
Malignancy risk: Low (but not zero)
Approach: Pregnancy test, review medications, infection screening, ultrasound if persistent
40-50 Years
Primary concerns: Structural pathology, anovulation, early malignancy
Malignancy risk: Increasing
Approach: Ultrasound for all, lower threshold for endometrial biopsy, especially with risk factors
Over 50 / Postmenopausal
Primary concerns: Malignancy, atrophy
Malignancy risk: High (10% of postmenopausal bleeding is cancer)
Approach: All cases need ultrasound and consideration of biopsy
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient is hemodynamically unstable | ABC assessment, IV access, fluid resuscitation, blood transfusion if needed | Urgent gynecology consultation; may need surgical intervention |
| Pregnancy test positive with pain | Assume ectopic until proven otherwise; urgent transvaginal ultrasound | If no intrauterine pregnancy: serial β-hCG, gynecology review, prepare for intervention |
| Visible cervical mass or suspicious lesion | Do NOT take cervical smear; document findings | Urgent colposcopy referral (two-week wait pathway) |
| Postmenopausal bleeding — first episode | Arrange transvaginal ultrasound within 2 weeks | If endometrium greater than 4 mm or unable to visualize: endometrial biopsy |
| Patient on anticoagulation with bleeding | Check anticoagulation levels (INR if on warfarin); investigate as per standard pathway | Liaise with anticoagulation service; do not assume bleeding is solely due to anticoagulant |
| Breakthrough bleeding on contraceptive less than 3 months | Reassurance; check compliance; exclude pregnancy if pills missed | Review in 3 months; if persistent, consider different formulation or investigate |
| Ultrasound shows fibroids | Document size, number, and location (submucosal most relevant to bleeding) | Refer to gynecology if symptomatic; submucosal fibroids may need hysteroscopic resection |
| Ultrasound shows endometrial polyp | Document size and characteristics | Refer for hysteroscopic polypectomy — both diagnostic and therapeutic |
| Endometrial biopsy shows hyperplasia without atypia | Progestogen therapy (oral or intrauterine device) | Follow-up biopsy in 3-6 months to confirm regression |
| Endometrial biopsy shows hyperplasia with atypia | Urgent gynecology oncology referral | Discuss hysterectomy versus progestogen therapy (if fertility desired) |
| Pipelle biopsy returns “insufficient sample” | Does not exclude pathology | Proceed to hysteroscopy with directed biopsy, especially if postmenopausal or high-risk |
Troubleshooting Persistent or Refractory Intermenstrual Bleeding
When Initial Investigations Are Normal but Bleeding Continues
- Was the diagnosis correct? Reconsider alternative causes; repeat history and examination
- Was the investigation adequate? Pipelle may miss focal lesions — consider hysteroscopy
- Was treatment given adequate time? Hormonal treatments may take 3 months to show effect
- Is there more than one cause? Multiple pathologies can coexist (e.g., fibroids AND polyp)
- Was compliance adequate? For hormonal management, confirm the patient is taking medication correctly
- Have you considered chronic endometritis? Often missed; requires endometrial biopsy with plasma cell analysis
- Have you considered coagulopathy? Especially if heavy bleeding since menarche
- Is specialist review needed? Consider referral if standard approach has not resolved symptoms
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Always test for pregnancy first: Regardless of contraceptive use, sexual history, or patient certainty, a pregnancy test is mandatory in all reproductive-age women with abnormal bleeding. Early ectopic pregnancy can be life-threatening.
Postmenopausal bleeding is cancer until proven otherwise: Approximately 10% of postmenopausal bleeding is due to endometrial carcinoma. Every case requires investigation with transvaginal ultrasound and consideration of endometrial biopsy.
Do NOT take a cervical smear if you see a suspicious lesion: If the cervix looks abnormal (mass, ulcer, friable tissue), refer directly for colposcopy. A smear may miss invasive cancer and delays diagnosis.
Contraceptive breakthrough bleeding is common and usually benign: Up to 50% of women starting hormonal contraception experience breakthrough bleeding in the first 3 months. Reassure, check compliance, and review — but do not ignore persistent bleeding.
Think about the source of bleeding: Confirm the bleeding is genuinely vaginal. Urethral and rectal sources are sometimes misidentified as vaginal bleeding. Ask the patient to observe carefully.
Multiple causes can coexist: A woman can have fibroids AND a polyp, or cervical ectropion AND endometrial pathology. Do not stop investigating after finding one abnormality if symptoms are not explained.
Chronic endometritis is underdiagnosed: Consider this in unexplained intermenstrual bleeding, especially with history of pelvic inflammatory disease, intrauterine procedures, or infertility. Diagnosis requires endometrial biopsy showing plasma cells.
Von Willebrand disease is the most common inherited bleeding disorder: Consider coagulopathy in women with heavy menstrual bleeding since menarche, easy bruising, or family history of bleeding. A normal platelet count does not exclude it.
Critical Pitfalls to Avoid
Assuming young women do not get cancer: While uncommon, cervical and endometrial cancer can occur in younger women. Do not dismiss persistent symptoms because of age alone — investigate appropriately.
Attributing all bleeding to contraceptives without examination: While breakthrough bleeding is common, always perform a speculum examination to visualize the cervix. A visible lesion should not be blamed on the contraceptive.
Reassuring based on a normal ultrasound alone: Ultrasound may miss small polyps, early endometrial pathology, and cervical lesions. A normal ultrasound does not exclude malignancy — clinical suspicion should guide further investigation.
Accepting “insufficient sample” on Pipelle biopsy as reassuring: An inadequate sample does not exclude pathology. If clinical concern is high, proceed to hysteroscopy with directed biopsy.
Ignoring bleeding on anticoagulation: While anticoagulants increase bleeding, they may also unmask underlying pathology. Investigate women on anticoagulation using the same approach as other patients.
Forgetting to ask about tamoxifen: Any bleeding in a woman on tamoxifen requires urgent investigation. Tamoxifen significantly increases the risk of endometrial polyps, hyperplasia, and cancer.
Delaying investigation of postmenopausal bleeding: Even a single episode of postmenopausal bleeding needs investigation. Do not adopt a “wait and see” approach — early endometrial cancer is highly curable.
Missing ectopic pregnancy: Any reproductive-age woman with bleeding and abdominal pain is ectopic until proven otherwise. A ruptured ectopic pregnancy is a surgical emergency. Always check β-hCG.
Key Takeaways
- Pregnancy first: Always exclude pregnancy with β-hCG in any reproductive-age woman with abnormal bleeding, regardless of contraceptive use or stated sexual activity.
- Age matters: The differential diagnosis and urgency of investigation change significantly with age. Malignancy risk increases with age, particularly after 40 and in postmenopausal women.
- Postmenopausal bleeding is urgent: All postmenopausal bleeding requires investigation. Endometrial cancer causes approximately 10% of cases and is curable if detected early.
- Examine the cervix: A speculum examination is essential. Do not take a cervical smear if a suspicious lesion is visible — refer directly for colposcopy.
- Use the PALM-COEIN framework: Systematically consider both structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified) causes.
- Transvaginal ultrasound is first-line imaging: It assesses endometrial thickness, identifies structural lesions, and guides further investigation. Best performed in the proliferative phase.
- Know when to biopsy: Endometrial sampling is indicated for postmenopausal bleeding, women over 45 with abnormal bleeding, thickened endometrium, and those with risk factors for endometrial cancer.
- Iatrogenic causes are common: Hormonal contraceptives, anticoagulants, and tamoxifen are frequent causes. Review medications in every patient but do not assume they are the only cause.
- Do not stop at the first diagnosis: Multiple pathologies can coexist. If treatment of one condition does not resolve symptoms, look for additional causes.
- Consider chronic endometritis: This underdiagnosed condition should be suspected in unexplained intermenstrual bleeding, especially with infertility or history of pelvic infection.
Quick Reference Algorithm
Systematic Approach to Intermenstrual Bleeding:
- Pregnancy test — mandatory in all reproductive-age women
- Assess stability — resuscitate if hemodynamically unstable
- Take a focused history — use the “BLEEDS” mnemonic; identify red flags
- Perform examination — including speculum to visualize the cervix
- Determine menopausal status — postmenopausal bleeding requires urgent investigation
- Review medications — identify contraceptives, anticoagulants, tamoxifen
- Arrange appropriate investigations — transvaginal ultrasound for most; infection screening if indicated
- Endometrial biopsy when indicated — postmenopausal bleeding, age over 45, risk factors, thickened endometrium
- Refer appropriately — urgent colposcopy for suspicious cervix; gynecology for structural pathology or abnormal biopsy
- Follow up — ensure symptoms resolve; reinvestigate if bleeding persists despite treatment